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A B S T R A C T   
Drug-drug interactions (DDI) potentially occurring between medications used in the course of COVID-19 
infection and medications prescribed for the management of underlying comorbidities may cause adverse 
drug reactions (ADRs) contributing to worsening of the clinical outcome in affected patients. First, we conducted 
a meta-analysis to determine comorbidities observed in the course of COVID-19 disease associated with an 
increased risk of worsened clinical outcome from 24 published studies. In addition, the potential risk of DDI 
between medications used in the course of COVID-19 treatment in these studies and those for the management of 
observed comorbidities was evaluated for possible worsening of the clinical outcome. Our meta-analysis revealed 
an implication cardiometabolic syndrome (e.g. cardiovascular disease, cerebrovascular disease, hypertension, 
and diabetes), chronic kidney disease and chronic obstructive pulmonary disease as main co-morbidities asso-
ciated with worsen the clinical outcomes including mortality (risk difference RD 0.12, 95 %-CI 0.05− 0.19, p =
0.001), admission to ICU (RD 0.10, 95 %-CI 0.04− 0.16, p = 0.001) and severe infection (RD 0.05, 95 %-CI 
0.01− 0.09, p = 0.01) in COVID-19 patients. Potential DDI on pharmacokinetic level were identified between the 
antiviral agents atazanavir and lopinavir/ritonavir and some drugs, used in the treatment of cardiovascular 
diseases such as antiarrhythmics and anti-coagulants possibly affecting the clinical outcome including cardiac 
injury or arrest because of QTc-time prolongation or bleeding. Concluding, DDI occurring in the course of anti- 
Covid-19 treatment and co-morbidities could lead to ADRs, increasing the risk of hospitalization, prolonged time 
to recovery or death on extreme cases. COVID-19 patients with cardiometabolic diseases, chronic kidney disease 
and chronic obstructive pulmonary disease should be subjected to particular carefully clinical monitoring of 
adverse events with a possibility of dose adjustment when necessary.   
1. Introduction 
The recent outbreak of the novel coronavirus officially known as 
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has 
progressed into global pandemic. Up to September 6, 2020 the World 
Health Organization (WHO) recorded 26,763,217 confirmed cases and 
876,616 deaths in 216 countries worldwide [1]. An estimated 20–51 % 
of affected patients are reported to have at least one comorbidity [2,3]. 
These affected patients with underlying comorbidities may have a 
greater risk of poor clinical outcome including severity, mortality, and 
admission to ICU [4–6]. Again, it is expected that given the percentage 
of individuals with comorbidities affected by the COVID-19, the use of 
polypharmacy for treatment of existing chronic disease conditions might 
be a routine. 
Since the inception of SARS-CoV-2 outbreak in the Chinese city of 
Wuhan in late 2019, several antiviral drugs and other medications 
currently utilized in clinics with known safety profile are repurposed in 
COVID-19 patients to reduce worsening of the symptoms [7,8]. On May 
1, 2020, the US Food and Drug Administration (FDA) issued an emer-
gency use authorization for the investigational antiviral drug remdesivir 
for the treatment of hospitalized adults and children with severe 
COVID-19 based on clinical trial data. Nonetheless, some of these drugs 
are known to cause severe drug-drug interactions (DDI) such as 
hydroxychloroquine and azathioprine leading to increased risk of 
QTc-time prolongations [9]. With respect to co-morbidities in COVID-19 
patients there is an additional potential risk of DDI between antiviral 
agents and multiple medications prescribed to treat their chronic disease 
conditions. It was shown that in northern Italy COVID-19 patients 
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experienced significant elevated plasma concentrations of direct oral 
anti-coagulants while on medications used in the course of COVID-19 
[10]. Unfortunately, with the exception of hydroxychloroquine and 
QTc-time prolongation due to co-administration of other drugs, the issue 
of potential harmful DDI in COVID-19 comorbid patients seems to be of 
minor attention with a limited number of published studies currently 
available [11–15]. Also, of a public health concern is the use of 
self-medication being potentially harmful or without evidence of clinical 
benefit taking place particularly in low- and middle-income countries 
with restricted access to quality healthcare and where drug dispensing is 
less controlled in the communities [16,17]. We hypothesized that in 
addition to comorbidities, DDI may further worsen the clinical outcome 
of COVID-19 in these patients. 
Herein, we first conducted a meta-analysis on COVID-19 clinical 
studies which characterized the epidemiological or clinical features of 
affected patients with comorbidities independent of pharmacological 
interventions. Secondly, the potential risk of DDI between drugs used in 
the course of COVID-19 and other medications prescribed for treatment 
of comorbidities were identified leading to potentially ADRs increasing 
the risk of poorer clinical outcome (e.g. hospitalization, prolonged time 
to recovery and death on extreme cases). 
2. Methods 
2.1. Search strategy and study criteria 
Electronic databases of PubMed, Medline, Scopus and google scholar 
were searched for articles published before June 17, 2020 in English- 
language reporting on COVID-19. A combination of search 
terminologies (“COVID-19”, “coronavirus”, “nCOV”, SARS-CoV-2”) 
AND (“clinical characteristics”) AND (“epidemiological features”) AND 
(“chronic diseases”) AND (“comorbidities”) were used for the search. 
Additional studies were obtained by examining the references of 
selected articles. Selection criteria for the analysis focused exclusively 
on clinical studies characterizing the clinical or epidemiological features 
of COVID-19 patients. Only studies with confirmed SARS-CoV-2-RNA 
detection in respiratory specimen including nasopharyngeal swabs, 
bronchoalveolar lavage fluid, sputum, or bronchial aspiration as well as 
in plasma were included in the meta-analysis. Clinical signs of the 
infection such as fever, cough, myalgia, malaise, rhinorrhea, arthralgia, 
chest pain and dyspnea were also taken into consideration. Other clin-
ical complications such as acute kidney and cardiac injuries were 
considered. We excluded studies conducted in children, pre-clinical 
models, case reports, letters, editorial commentaries, reviews, and 
meta-analysis. 
2.2. Statistical analysis 
The risk difference method was used to estimate weights of indi-
vidual study outcome using the Mantel-Haenszel method with random- 
effect model in the R statistical software (version 3.4.2). The statistical 
heterogeneity between study outcomes were visualized using the forest 
plot and the inter-study heterogeneity estimated by calculating the Ԏ2, I2 
and H2 statistics, and by computing Cochran’s Q test statistics [18,19]. 
An I2 values lower than 25 % was considered as low heterogeneity, 
values of 26–50 % indicated moderate heterogeneity and values greater 
than 50 % to indicate a high heterogeneity. A Cochran’s Q test statistics 
with p-value of < 0.05 was an indication of statistical significance 
Fig. 1. Flow diagram indicating publications on clinical COVID-19 studies excluded and included in the meta-analysis.  
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heterogeneity. The trim and fill method was used to determine hypo-
thetical missing studies as evidence of publication bias when necessary 
(Supplementary Fig. 1). 
2.3. Potential drug-drug interactions 
The data on drugs used in the course of COVID-19 and the primary 
indication were collected from www.ashp.org/COVID-19 as well as 
metabolizing enzymes involved in their biotransformation from www.dr 
ugbank.ca. The potential of drugs used in the course of COVID-19 
infection reported in the included studies to interact with other drugs 
used for the management of comorbidities which could precipitate ADRs 
likely to further worsen clinical outcome of COVID-19 based on our 
meta-analysis was assessed using the www.covid19-druginteractions. 
org database. Here, potential DDIs are classified into four groups: (i) 
no clinically significant interaction expected; (ii) potential interaction 
likely to be of weak intensity with monitoring or dosage adjustment 
unlikely to be required; (iii) potential clinically significant interaction 
that may require close monitoring, alteration of drug dosage or timing of 
administration; and (iv) drugs should not be co-administered. We sub-
sequently focused our analysis only on the latter. The clinical relevance 
of such DDI were risk ranked into five categories based on the quality of 
evidence as: (0) unlikely - no evidence of preclinical or clinically sig-
nificant interaction, (1) very low - in vitro or animal studies, single case 
reports, parallel or crossover single dose pharmacokinetic (PK) study 
without area under plasma concentrations (AUCs), PK study in infected 
or healthy subjects, (2) low - multiple case reports, crossover or parallel 
steady state PK without AUCs, parallel or crossover single dose PK study 
with AUCs, metabolism study with probe substrates, observational PK in 
infected patients, (3) moderate - cross-over, parallel steady state PK 
study with AUCs and (4) high - data based on randomized, controlled 
interaction trial with clinical or validated surrogate endpoints. 
The grading on quality of evidence of DDI was conducted for each 
medication prescribed for the treatment or management of comorbid-
ities against individual COVID-19 therapies. Subsequently, the z-score 
was calculated and used to construct heatmaps in www. software. 
broadinstitute.org/morpheus. 
3. Results 
3.1. Study characteristics 
A literature search was conducted to extract eligible studies for the 
meta-analysis. Of 467 records screened for eligibility, 24 prospective 
and retrospective case studies with a total of 5,586 COVID-19 affected 
patients were included in the meta-analysis (Fig. 1). Data on the un-
derlying comorbidities was drawn from the reported clinical charac-
terization of the affected patients. Comorbidities reported include 
cardiovascular diseases, cerebrovascular disease, chronic kidney dis-
ease, chronic liver disease, chronic obstructive pulmonary disease 
(COPD), hypertension, diabetes, malignancy, human immunodeficiency 
virus (HIV) and others. The mean age of the affected patients ranged 
from 41 years to 63 years (Table 1). 
Table 1 
Clinical characteristics of COVID-19 patients included in 24 eligible studies.  
Author (year) Origin Design Age 
(years) 
Number of Patients     
All CVD CRV CKD CLD Diabetes Hypertension Malignancy COPD 
Cao et al., 2019 [47] China NA 54 102 5 (5%) 6 (6%) 4 (4%) 2 (2%) 11 (11 %) 28 (28 %) 4 (4%) 10 (10 
%) 
Chen et al., 2020 [48] China RD 62 274 23 (8%) NA NA NA 47 (17 %) 93 (34 %) 7 (3%) 18 (7%) 
Deng et al., 2020 [49] China RD NA 225 NA NA NA NA NA NA NA NA 
Feng et al., 2020 [50] China RD 53 476 38 (8%) 17 (4%) NA NA 49 (10 %) 113 (24 %) 12 (3%) 22 (5%) 
Guan et al., 2020 [51] China PD 47 1099 27 (3%) 15 (1%) 8 (1%) NA 81 (7%) 165 (15 %) 10 (1%) 12 (1%) 
Huang et al., 2020 [2] China PD 49 41 6 (15 %) NA NA 1 (2%) 8 (20 %) 6 (15 %) 1 (2%) 1 (2%) 
Huang et al., 2020 [52] China RD 44 202 NA NA NA NA 19 (9%) 29 (14 %) NA NA 
Itelman et al., 2020 
[53] 
Israel RD 52 162 NA NA 2 (1%) NA 30 (19 %) 49 (30 %) NA 2 (1%) 
Javanian et al., 2020 
[54] 
Iran RD 60 100 20 (20 
%) 
NA 12 (12 
%) 
NA 37 (37 %) 32 (32 %) 4 (4%) 12 (12 
%) 
Liu et al., 2020 [55] China RD 49 40 NA NA NA NA 6 (15 %) 6 (15 %) NA NA 
Shi et al., 2020 [56] China RD 63 671 60 (9%) 22 (3%) 28 (4%) NA 97 (15 %) 199 (30 %) 23 (3%) 23 (3%) 
Sun et al., 2020 [57] China RD 44 55 NA NA NA NA 5 (9%) 8 (15 %) NA NA 
Wan et al., 2020 [58] China RD 47 135 7 (5%) NA NA 2 (2%) 12 (9%) 13 (10 %) 4 (3%) NA 
Wang et al., 2020 [6] China RD 56 138 20 (15 
%) 
7 (5%) 4 (3%) 4 (3%) 14 (10 %) 43 (31 %) 7 (10 %) 4 (3%) 
Wang et al 2020 [59] China RD 51 107 13 (12 
%) 
6 (6%) 3 (3%) 6 (6%) 11 (10 %) 26 (24 %) NA 3 (3%) 
Wu et al., 2020 [60] China RD 43 280 57 (20 
%) 
NA 3 (1%) 7 (3%) NA NA 5 (2%) NA 
Xie et al., 2020 [61] China RD 60 79 7 (9%) NA NA NA 8 (10 %) 14 (18 %) NA NA 
Xu et al., 2020 [62] China RD 41 62 NA 1 (2%) 1 (2%) 7 (11 
%) 
1 (2%) 5 (8%) NA 1 (2%) 
Xu et al., 2020 [63] China RD 46 703 35 (5%) NA 10 (1%) 29 (4%) 64 (9%) 118 (17 %) 9 (1%) 13 (2%) 
Yang et al., 2020 [4] China RD 59.7 52 5 (10 %) 7 (14 
%) 
NA NA 9 (17 %) NA 2 (4%) 4 (8%) 
Zhang et al., 2020 [64] China RD 57 140 7 (5%) NA NA NA 17 (12 %) 42 (30 %) NA 2 (1%) 
Zheng et al., 2020 [65] China RD 45 161 4 (3%) 4 (3%) NA 4 (3%) 7 (4%) 22 (14 %) NA 6 (4%) 
Zhao et al., 2020 [66] China RD 46 91 NA NA 1 (1%) NA 3 (3%) NA 3 (3%) 1 (1%) 
Zhou et al., 2020 [67] China RD 56 191 15 (8%) NA 2 (1%) NA 36 (19 %) 58 (30 %) 2 (1%) 6 (3%) 
*Median or average age (years. Abbreviations: cardiovascular disease (CVD), cerebrovascular disease (CRV), chronic kidney disease (CKD) and chronic liver disease. 
(CLD), retrospective design (RD), prospective design (PD), not specified (NS), not available (NA). 
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3.2. Meta-analysis 
Based on the 24 identified eligible studies, a meta-analysis was 
conducted to determine comorbidities which may be associated with an 
increased risk of clinical outcome in COVID-19 affected patients. For the 
meta-analysis, we separated the comorbidities based on non-survivors 
vs. survivors, ICU vs. non-ICU and severity vs. mild cases depending 
on the clinical presentations of signs and symptoms of the COVID-19 
patients as reported by individual studies. In general, we observed 
poorer clinical outcome for COVID-19 patients with co-morbidities in 
ascending order of severe vs. mild (risk difference (RD) 0.05, 95 % CI 
0.01 – 0.09, p = 0.01), ICU vs. non-ICU (RD 0.10, 95 % CI 0.04− 0.16, p 
= 0.001), and non-survivors vs. survivors (RD 0.12, 95 % CI 0.05 – 0.19, 
p = 0.001) (Fig. 2). The analysis on non-survivors vs. survivors group 
showed hypertension, cardiovascular disease, diabetes, cerebrovascular 
disease, chronic kidney disease and malignancies were associated with 
significant increase in risk of death among COVID-19 patients. Other 
diseases including COPD and chronic liver disease had no impact on the 
risk of death among infected patients, for details see Fig. 2. For cases 
admitted to ICU, affected patients with cerebrovascular disease showed 
a high risk (RD 0.16, 95 % CI 0.03 – 0.28, p = 0.01) but the data was 
insufficient to strengthen the outcome (Fig. 2). Similarly, the analysis on 
severe vs. mild COVID-19 infection indicated that hypertension, dia-
betes, and COPD were associated with increase severity of infection in 
patients as depicted in Fig. 2. Cardiovascular disease was a borderline 
risk factor in severe COVID-19 patients. The meta-analyses on individual 
studies included in respective groups are shown in supplementary 
Figs. 2–4. 
In subgroup analyses, low statistical heterogeneity was found in 
those (non-survivors vs. survivors) with chronic kidney disease (I2 26.0, 
Q 5.39) and diabetes (I2 21.0, Q 10.5), and high heterogeneity in pa-
tients with COPD (I2 52.0, Q 8.37) and cardiovascular disease (I2 70.0, Q 
26.4). Patients (those in ICU vs. non-ICU) with diabetes (I2 84.8 %, Q 
6.56) and hypertension (I2 83.1, Q 5.92) showed high heterogeneity. In 
addition, high heterogeneity was indicated in patients (those with se-
vere vs mild) with diabetes (I2 56.2, Q 22.82), hypertension (I2 66.6, Q 
27.0), and cardiovascular disease (I2 90.4, Q 62.74) as shown in Table 2. 
3.3. Potential drug-drug interactions 
From the meta-analysis, comorbidities associated with increased risk 
of worsen clinical outcome in COVID-19 patients were cardiovascular 
disease, cerebrovascular disease, hypertension, diabetes, chronic kidney 
disease and chronic obstructive pulmonary disease. Further, several 
drugs have been used in different countries in the course of COVID-19 
infection as reported in various studies included in the meta-analysis. 
Hence, we further used the www.covid19-druginteractions.org data-
base to estimate the potential interaction risk of antiarrhythmics, anti-
hypertensives, anticoagulants, antidiabetics, lipid lowering medications 
(statins), and bronchodilators with drugs used in the course of COVID-19 
patients. A list of 41 drugs used in the course of COVID-19, their primary 
indication as well as main metabolizing enzymes are documented in 
Table 3. The use of hydroxychloroquine and lopinavir/ritonavir in 
COVID-19 was suspended or stopped in the WHO SOLIDARITY trial. 
According to the International Steering Committee interim trial report, 
hydroxychloroquine and lopinavir/ritonavir produced little or no 
decline in the mortality of hospitalized COVID-19 patients when 
compared to standard of care (www.who.int/news-room/detail 
/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ri 
tonavir-treatment-arms-for-covid-19). However, these drugs are still 
used for the COVID-19 infection at some hospitals in other countries. 
Hence, both drugs were included in our DDI analysis. 
According to the analysis, co-administration of some drugs used for 
the treatment or management of comorbidities together with atazanavir 
and lopinavir/ritonavir (used as therapies for COVID-19) could increase 
the risk of adverse outcome of COVID-19 patients by evidence of po-
tential pharmacokinetic interactions. E.g. an increase in plasma expo-
sure of antiarrhythmics (e.g. amiodarone, bepridil, disopyramide, 
Fig. 2. Meta-analysis of comorbidities in COVID-19 patients and typical related drugs. Cardiometabolic syndrome (cardiovascular disease, hypertension, and dia-
betes) was associated with worse clinical outcome of COVID-19 in affected patients. Drugs used for management or treatment of comorbidities: antihypertensives, 
antiarrhythmics, lipid lowering drugs (statins) listed could increase poor clinical outcome in comorbid patients by potential interaction with drugs used in the course 
of COVID-19. *indication for both pulmonary hypertension and erectile dysfunction. 
C. Awortwe and I. Cascorbi                                                                                                                                                                                                                  
Pharmacological Research 161 (2020) 105250
5
dofetilide, flecainide and quinidine), drugs prescribed for pulmonary 
hypertension (e.g. bosentan and sildenafil), angina pectoris (e.g. rano-
lazine), heart failure (e.g. eplerenone, ivabradine), erectile dysfunction 
(e.g. sildenafil), few anti-hypertensives (e.g. aliskiren and lercanidi-
pine), antithrombotics and anticoagulants (e.g. ticagrelor and rivarox-
aban), and statins (e.g. lovastatin and simvastatin) was detected due to a 
potential inhibition mainly of CYP3A4 by atazanavir or lopinavir/rito-
navir (Fig. 3). Additionally, atazanavir and lopinavir/ritonavir may in-
crease plasma concentrations of the anti-coagulant dabigatran by 
inhibiting the efflux drug transporter P-glycoprotein (P-gp). The HIV- 
protease inhibitor atazanavir was also shown before to inhibit 
CYP3A4, CYP2C8 and hepatic transporter OATP1B1 thereby increasing 
systemic exposure of antidiabetic drug repaglinide. The protease in-
hibitors lopinavir/ritonavir may also increase plasma exposure of the 
bronchodilator salmeterol via CYP3A4 inhibition. Azithromycin, chlo-
roquine, or hydroxychloroquine used in the frame of COVID-19 treat-
ment are prone to cause QTc-time prolongation in the presence of 
antiarrhythmics as a single agent or combined due to pharmacodynamic 
interactions. The summary of drugs used in the course of COVID-19 
identified to cause clinically relevant interactions with other medica-
tions for the related co-morbidities are presented in Table 4. 
We further estimated the potential interaction of combination ther-
apies (e.g. azithromycin/nitazoxanide, hydroxychloroquine/azi-
thromycin, and INF-β-1a/lopinavir-ritonavir/ribavirin) for COVID-19 
because some of the included studies reported coadministration of these 
medications. In general, lack of evidence of clinically significant DDI 
was found. Potential interaction between other COVID-19 drugs (e.g. 
remdesvir, darunavir/cobistat, favipiravir, nitazoxanide, ribavirin, 
tocilizumab, sarilumab, IFN-β-1a, oseltamivir and anakinra) and co- 
medications prescribed for the treatment of existing comorbidities 
identified based on the meta-analysis were found to be of a low 
certainty. 
4. Discussion 
Comorbidities associated with poor clinical outcome of COVID-19 in 
affected patients are widely reported in other studies [20–22]. The re-
sults of our meta-analysis confirmed hypertension, cardiovascular dis-
ease, and diabetes being strongly associated with increased mortality 
and severe courses of COVID-19. Patients with cerebrovascular disease 
were more likely to be admitted to ICU or even die. Interestingly, in the 
set of studies included into the meta-analysis, chronic kidney disease 
and malignancies were associated with increasing the risk of mortality 
whilst COPD increases the severity of COVID-19 in affected patients. In 
general, patients with these underlying comorbidities have greater risk 
of upper respiratory tract infections and pneumonia because of 
dysfunctional innate and adaptive immune system [20,22]. 
Current treatment of COVID-19 primarily depends on supportive 
care, antiviral and immunomodulatory drugs. Given the distribution of 
population living with the comorbidities (hypertension, cardio- 
cerebrovascular, diabetes, chronic kidney disease), predominantly 
middle aged and elderly, polypharmacy and DDI might be apparent. 
Unfortunately, the potential risk of DDI is largely unknown since most 
studies on COVID-19 do not provide details on interaction between 
drugs used in the course of COVID-19 and co-medications used for the 
management of other comorbidities in these patients. The studies 
included in the meta-analysis indicated several medications used in the 
course of COVID-19 in infected patients with other underlying comor-
bidities. Hence, we evaluated the potential interaction of drugs for the 
treatment of these comorbidities with drugs for COVID-19 reported in 
studies included in the meta-analysis. Based on our findings, of a greater 
safety concern was prolonged cardiac repolarization and QT interval by 
pharmacokinetic interaction of atazanavir and lopinavir/ritonavir with 
some drugs, used in the treatment of cardiovascular diseases such as 
ivabradine in heart failure, ranolazine in symptomatic treatment of 
angina pectoris, the antiarrhythmics amiodarone disopyramide and 
quinidine or the formerly used calcium channel blocker bepridil (a drug 
with putative anti-viral properties) via inhibition of CYP3A4 which may 
further increase the risk of torsade de pointes (TdP) [23–25]. Conse-
quences of such interaction may increase risk of hospitalization, pro-
longed time to recovery and finally sudden cardiac death in extreme 
cases. Other risk factors of QTc-time prolongation and TdP include hy-
pokalemia and chronic heart failure. Furthermore, atazanavir and 
lopinavir/ritonavir could interact with antithrombotics and anticoagu-
lants (e.g. ticagrelor, dabigatran and rivaroxaban) through CYP3A4 and 
P-glycoprotein to induce bleeding complication [10]. Interestingly, a 
recent retrospective study found the use of statins in hospitalized 
Table 2 
Results of meta-analysis and subgroup analysis on comorbidities in COVID-19 
patients.  
Condition Point estimate 
[95 % CI] 
P value Heterogeneity 
I2 (%) Q Ʈ2 
Non-survivors vs 
survivors      
Cardiovascular 
disease 










0.001 26.0 53.9 – 
Chronic liver disease 0.01 [-0.07; 
0.10] 
0.72 – 0.23 – 
COPD 0.05 [-0.01; 
0.11] 
0.10 52.0 8.37 – 
Diabetes 0.14 [0.08; 
0.19] 
<00000.1 21.0 10.15 – 
Hypertension 0.29 [0.23; 
0.34] 
<0.00001 – 6.78 0.010 
Malignancy 0.04 [0.01; 
0.06] 
0.008 – 1.91 –  










0.38 – – – 
COPD 0.07 [-0.02; 
0.17] 
0.12 – – – 
Diabetes 0.01 [-0.33; 
0.34] 
0.98 84.8 6.56 0.050 
Hypertension 0.20 [-0.16; 
0.56] 
0.28 83.1 5.92 0.060 
Malignancy 0.05 [-0.06; 
0.16] 
0.36 – – –  















0.24 – – – 
Chronic liver disease 0.03 [-0.02; 
0.08] 
0.19 – 0.04 – 
COPD 0.03 [0.00; 
0.06] 
0.003 – 0.03 – 
Diabetes 0.08 [0.02; 
0.14] 
0.002 56.2 22.82 0.004 
Hypertension 0.10 [0.08; 
0.20] 
0.007 66.6 26.97 0.010 
Malignancy 0.01 [0.00; 
0.03] 
0.13 – 2.61 – 
*COPD = chronic obstructive pulmonary disease. 
C. Awortwe and I. Cascorbi                                                                                                                                                                                                                  
Pharmacological Research 161 (2020) 105250
6
COVID-19 patients to be associated with a lower risk of all-cause mor-
tality and a favorable recovery profile compared to the non-statin group 
[26]. However, with regards to DDI, statins (e.g. lovastatin and simva-
statin) may induce myopathy as consequence of an elevated plasma 
concentration of these statins because of CYP3A4 inhibition by ataza-
navir and lopinavir/ritonavir. For example, the AUC of statins lovastatin 
and simvastatin increased in the presence of ritonavir by up to 20-fold 
[27–29]. Hence, the use of less DDI-proned statins should be 
preferred. In Asthma, plasma concentration of salmeterol could increase 
due to inhibition of CYP3A4 by lopinavir/ritonavir. Such combination 
may result in salmeterol related side-effects including QTc-time pro-
longation, palpitations, and tachycardia [28,30]. 
Adverse events detected in these patients while co-treatment with 
drugs used in the course of COVID-19 e.g. azithromycin, chloroquine, 
and hydroxychloroquine and anti-hypertensives are not based on 
pharmacokinetic interactions but on known risks of TdP by prolonged 
cardiac polarization and QT interval of such combinations [31–33]. 
Nonetheless, hydroxychloroquine and chloroquine are also known to be 
Table 3 
Drugs used in the course of COVID-19 disease, classification, primary indication and main metabolic pathways.  






ACE Inhibitors, Angiotensin II 
Receptor Blockers (ARBs) 
Renin angiotensin 
aldosterone system (RAAS) 
inhibitor 
High blood pressure and heart failure 
– – – 
CYP2C9 – – 
Alteplase Plasmin activator 
Acute ST elevation myocardial infarction (STEMI), 
pulmonary embolism – – – 
Anakinra Disease modifying anti- 
rheumatic agent 
RA – – – 
Ascorbic acid Vitamin C Vitamin C deficiency – – – 
Atazanavir HIV protease inhibitors HIV infection CYP3A4 CYP3A4 – 
Azithromycin Macrolides Multiple bacterial infections – – – 
Baloxavir Antiviral Influenza – – – 
Baricitinib 
Disease-modifying anti- 
rheumatic agent Moderate to severe RA CYP3A4 – – 
Bevacizumab IgG1 antibody Various cancer types – – – 
Chloroquine phosphate Antimalarial (4- 
aminoquinoline derivative) 
Malaria CYP2C8, CYP3A4 CYP2D6 – 
Colchicine Antigout agents Gout CYP3A4, P-gp – – 
Darunavir/cobicistat HIV protease inhibitors HIV infection CYP3A – – 
Emapalumab Anti-interferon gamma hemophagocytic lymphohistiocytosis –   
Famotidine Histamine H2 antagonists 
Peptic ulcer disease, gastroesophageal reflux 
disease, Zollinger-Ellison syndrome –   
Favipiravir Antiviral Influenza Aldehyde oxidase – – 
Fingolimod Immunosuppressant Multiple sclerosis Sphingosine kinase, CYP4F2 – – 
HMG-CoA reductase inhibitors 
(statins) 




Malaria, auto-immune diseases (lupus, 
rheumatoid arthritis) CYP3A4 CYP2D6 – 
Inhaled prostacyclins (e.g. 
epoprostenol, iloprost) Vasodilating agents Pulmonary arterial hypertension – – – 
Interferon beta 1a Interferon Multiple sclerosis – – – 
Ivermectin Anthelmintic Multiple parasitic infections P-gp – – 
Lopinavir HIV protease inhibitor HIV infection CYP3A CYP3A4 – 





N-acetylcysteine Antioxidant Acetaminophen overdose – – – 
Niclosamide Anthelmintic Tapeworm infestations CYP1A2, UGT1A1 – – 
Nitazoxanide Antiprotozoal GIT infections – – – 
Nitric oxide (inhaled) Vasodilating Agent Neonatal respiratory failure – – – 




Pain, fever, inflammation CYP2C8/9, CYP2C19, UGT2B7 – – 
Oseltamivir Neuraminidase inhibitor Influenza Esterases – – 
Peg-interferon alpha 2b Interferon Hepatitis C and melanoma – – – 
Remdesivir Antiviral *COVID-19 CYP2C8, CYP2D6, CYP3A4 – – 
Ribavirin  Hepatitis C Adenosine kinase   
Ritonavir HIV protease inhibitors HIV infection CYP3A/CYP2D6 CYP3A4, 
P-gp 
– 
Ruxolitinib Antineoplastic Agents Bone marrow disorders CYP3A4 P-gp – 
Sarilumab 
Disease modifying anti 
-rheumatic agent Moderate to severe RA in adults – – – 
Sildenafil PDE5 inhibitor 
Erectile dysfunction, pulmonary arterial 
hypertension CYP3A4/CYP2C9 – – 
Siltuximab Monoclonal antibody Multicentric Castleman’s disease – – – 
Sirolimus Immunosuppressive agent 
(mTOR inhibitor 
Prevent rejection of kidney transplant CYP3A4 – – 
Tocilizumab Disease-modifying 
antirheumatic agent 
Moderate to severe rheumatoid arthritis (RA) in 
adults, systemic juvenile idiopathic arthritis-SJIA, 
other rheumatological conditions 
Proteolytic enzymes – – 
Umifenovir Antiviral Influenza CYP3A4, UGT1A9, UGT2B7 – –  
* FDA and EMA emergency use authorization. 
b Metabolizing enzymes information collected from Drugbank and product information, drug list data obtained from https://www.ashp.org/COVID-19. 
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inhibitors of cytochrome P450 2D6 (CYP2D6) hence contributing to an 
increased risk of TdP of the older antiarrhythmics flecainide and mex-
iletine [32–35]. Here, adjusting the recommended dose of hydroxy-
chloroquine from 800 mg on day 1, followed by 400 mg daily for 4–7 
days to a lower dose may be necessary to avoid potential adverse events 
(https://www.fda.gov/media/136537/download). 
We additionally considered the potential interaction of combination 
therapies for COVID-19 azithromycin/nitazoxanide, hydroxy-
chloroquine/azithromycin, tocilizumab/remdesivir, and triple combi-
nation (IFN-β-1a, lopinavir/ritonavir and ribavirin) used to tackle the 
pandemic. Studies have shown synergistic effects of these combinations 
therapies on inhibition of SARS-CoV-2 replication [36–39]. Generally, 
DDI of such combinations are uncertain due to lack of evidence. The 
azithromycin/hydroxychloroquine combination related TdP may occur 
as side effect of single or both drugs [31–33,37]. The antimalaria agent 
hydroxychloroquine is an inhibitor of P-glycoprotein [40]. However, 
pharmacokinetic interaction of azithromycin with hydroxychloroquine 
is unexpected because the former is not a sensitive substrate of 
P-glycoprotein [40,41]. Besides, hydroxychloroquine has long terminal 
elimination half-life (40–60 days) which may cause the risk of cardiac 
polarization and QT prolongation to persist even after discontinuation 
[34,42]. 
Prediction of DDI however could be hampered, since COVID-19 pa-
tients may experience phenoconversion whereby some genotypic 
extensive metabolizers transiently exhibit a decline in drug metabo-
lizing enzyme activities comparable to that of poor metabolizers because 
of cytokine storm [43,44]. The problem of phenoconversion due to 
hyperactive immune system may increase the cardiac related side effects 
of drugs used in the course of COVID-19 (e.g. hydroxychloroquine) as 
consequence of prolonged plasma exposure [31,33,42]. Additionally, 
genetic polymorphism in drug metabolizing enzymes and transporters 
might worsen the side effects of drugs used for COVID-19 or in combi-
nation with other medications in individuals with defective genes. 
On the other side, drugs used in the main regimens of hypertension, 
heart failure or diabetes did not show evidence of DDIs. In particular 
inhibitors of the renin angiotensin aldosterone system (RAAS) seem to 
be safe and concerns that the treatment with ACE-inhibitors could in-
crease the risk of SARS-CoV-2 infections through elevation of the ACE-2 
expression were not confirmed so far [45,46]. 
In conclusion, comorbidities including cardio-cerebrovascular dis-
eases, hypertension, diabetes, and chronic kidney disease were associ-
ated with increased severity and mortality of COVID-19 in affected 
patients. DDI may be evident in these patients due to the use of poly-
pharmacy as found in studies included in this meta-analysis. We have 
shown potential DDI particularly between antiretroviral drugs (ataza-
navir and lopinavir/ritonavir), and other drugs for treating comorbidity 
leading to TdP which might contribute to poorer clinical outcome (e.g. 
increased risk of hospitalization, prolonged time to recovery and death 
on extreme cases) in COVID-19 patients. This study cannot confirm 
whether the consequences of the DDI described change the expected 
course of COVID-19 since there are no clinical data available. To avoid 
adverse DDI, dose adjustment of drugs used in the course of COVID-19 
prone to DDI or using an alternative drug for the management of 
related co-morbidity may be warranted to prevent risk of worsening 
clinical outcome. The findings of our study add to the knowledge on the 
potential risk of DDI in comorbid COVID-19 patients which is still an 
evolving area. It is worth noting that, this article is not intended to 
prevent the use of any medication but to outline the potential risk of 
specific DDIs which may further worsen the clinical outcome of COVID- 
19 patients with these comorbidities. Taken together, the choice of 
administration of medication in COVID-19 patients with comorbidities 
remains sole prerogative of the prescriber. However, we recommend 
that attention should be paid to symptoms that could indicate drug side 
effects in particular cardiac arrhythmia via DDI in these special 
population. 
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Fig. 3. Heatmap of potential DDI between drugs used in the course of COVID- 
19 and co-medications. The co-medications are putatively used for treatment of 
identified comorbidities (hypertension, cerebrovascular, cardiovascular, dia-
betes and COPD) based on results of the meta-analysis. Anti-viral drugs LPV/r 
and AZM interact with drugs prescribed for cardiometabolic syndrome. Po-
tential interactions were predicting using www.covid19-druginteractions.org 
database. Abbreviations: atazanavir (ATV), azithromycin (AZM) darunavir/ 
cobicistat (DRV/c), lopinavir/ritonavir (LPV/r), remdesivir/GS-5734 (RDV), 
favipiravir (FAVI), chloroquine (CLQ), hydroxychloroquine (HCLQ), nitazox-
anide (NITA), ribavirin (RBV), tocilizumab (TCZ), interferon β-1a (IFN-β-1a) 
and oseltamivir (OSV). 
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Example of interaction 




Apixaban 50 92 - 94 Lopinavir/ritonavir CYP3A4 Ketoconazole increases 












concentration by 44 % 
via CYP3A4 inhibition 
Increased amiodarone 




Use with caution, monitor 
ECG, and adjust 
amiodarone 
Bepridil 60 99 Atazanavir, 
lopinavir/ritonavir 
– – Increased bepridil level 
effects. E.g. (QTc-time 
prolongation, 
hypotension 
Do not co-administer 
Bosentan 50 98 Atazanavir – Expected decreased 
atazanavir levels 
Potential loss of 
antiviral activity 
Do not co-administer 
bosentan with un-boosted 
atazanavir 




110− 127% via 
inhibition of intestinal 
P-gp by cobicistat 
Increased risk of 
bleeding because of 
elevated dabigatran 
level 
No dose adjustment if CrCL 
> 50 mL/min. avoid co- 
usage if CrCL < 50 mL/min 







AUC by 44 % 
Increased plasma 
concentration, risk of 
hyperkalemia 
Avoid co-administration 




– Increased plasma 
concentration 
Monitor and adjust 
lercanidipine levels 




– Possible increased 
mexiletine effect e.g. 
Cardiac arrythmias 
Do not co-administer 
Quinidine 76 - 88 80 - 88 Atazanavir CYP3A4 
inhibition  
Enhanced quinidine 
effects e.g. cardiac 
arrhythmia 
Use with caution. Monitor 
for toxicity 









Do not co-administer 




AUC by 40 % 
Increase risk of 
hypoglycemia 
Monitor repaglinide 
clinical effect and lower 
the dose if necessary 
Salmeterol – 96 Lopinavir/ritonavir CYP3A4 
inhibition 
– Potential increased 




Do not co-administer 




sildenafil AUC by 128 % 





Start sildenafil at 25 mg 
QOD-QD; adjust dose, not 
recommended to exceed 
25 mg in a 48 h period 




exposure increased by 




concentration effects (e. 
g. myopathy, 
rhabdomyolysis) 
Do not co-administer. 
Alternative agents e.g. 
atorvastatin (low dose), 
pravastatin 
Lovastatin 5 >95  
* Bioavailability and protein binding information collected from Drugbank and product information. 
b Recommendations obtained from http://hivinsite.ucsf.edu/interactions. 
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